证券代码：688065 证券简称：凯赛生物 公告编号：2023-050 上海凯赛生物技术股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日向全 体监事以邮件方式发出会议通知，并于 2023 年 8 月 17 日以通讯会议的方式召开第二 届监事会第十一次会议。本次会议由监事会主席张国华主持，会议应到 3 人，实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规、规章、规范性文件和《上海凯赛生物技术股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于调整 2022 年限制性股票激励计划授予价格的议案》 公司监事会对 2022 年限制性股票激励计划（以下简称"本激励计划"）授予价 格的调整事项进行了核查，监事会认为： 鉴于公司 2022 年年度权益分派 ...

2023 年半年度报告 公司代码：688065 公司简称：凯赛生物 上海凯赛生物技术股份有限公司 2023 年半年度报告 1 / 199 2023 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中描述公司面临的风险，敬请查阅本报告第三节"管理层讨论与分析"中 "五、风险因素"相关内容，请投资者予以关注。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人 XIUCAI LIU(刘修才)、主管会计工作负责人杨文颖及会计机构负责人（会计主 管人员）陈霄堃声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、 是否存在被控股股东及其 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2023-045 上海凯赛生物技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 14 日(星期一) 下午 13:00-14:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 7 日(星期一)至 8 月 11 日(星期五)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 cathaybiotech_info@cathaybiotech.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 上海凯赛生物技术股份有限公司（以下简称"公司"）将于 2023 年 8 月 8 日 发布公司 2023 年 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥505,446,207.40, representing a decrease of 23.56% compared to the same period last year[4] - The net profit attributable to shareholders was ¥57,441,388.49, down 67.09% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥45,784,034.69, a decline of 72.83% compared to the previous year[4] - The net cash flow from operating activities was ¥79,246,727.84, reflecting a decrease of 45.14% year-on-year[4] - Total revenue for Q1 2023 was ¥505.45 million, a decrease of 23.5% compared to ¥661.27 million in Q1 2022[18] - Operating profit for Q1 2023 was ¥79.09 million, down 63.3% from ¥215.52 million in Q1 2022[20] - Net profit for Q1 2023 was ¥71.85 million, a decline of 62.5% compared to ¥191.35 million in Q1 2022[20] - Cash flow from operating activities for Q1 2023 was ¥79.25 million, down 45.1% from ¥144.46 million in Q1 2022[23] - Cash received from sales of goods and services was ¥485.11 million in Q1 2023, a decrease of 21.0% from ¥614.01 million in Q1 2022[22] - Total operating costs for Q1 2023 were ¥441.82 million, slightly down by 1.8% from ¥449.65 million in Q1 2022[18] - Basic earnings per share for Q1 2023 were ¥0.10, down from ¥0.30 in Q1 2022[21] - Investment income for Q1 2023 was a loss of ¥1.33 million, compared to a loss of ¥0.81 million in Q1 2022[20] - Other income for Q1 2023 was ¥14.65 million, an increase of 117.5% from ¥6.76 million in Q1 2022[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥18,199,553,058.74, an increase of 2.09% from the end of the previous year[5] - As of March 31, 2023, the total assets of the company amounted to ¥18,199,553,058.74, an increase from ¥17,827,280,594.67 at the end of 2022, reflecting a growth of approximately 2.08%[14] - The company's current assets totaled ¥8,273,543,291.51, down from ¥8,475,498,571.63, indicating a decrease of about 2.4%[15] - The cash and cash equivalents were reported at ¥6,089,118,605.06, a decrease from ¥6,294,603,629.16, representing a decline of approximately 3.25%[14] - The company's total liabilities increased to ¥3,085,297,996.81 from ¥2,789,068,039.70, marking an increase of about 10.65%[16] - The total equity attributable to shareholders rose to ¥11,010,586,170.23 from ¥10,948,955,346.19, reflecting an increase of approximately 0.56%[17] - The company's accounts receivable decreased to ¥338,722,525.06 from ¥390,400,888.63, a decline of about 13.24%[14] - The inventory value was reported at ¥1,557,074,504.08, slightly down from ¥1,573,637,818.64, indicating a decrease of approximately 1.06%[15] - The short-term borrowings increased significantly to ¥426,517,380.00 from ¥161,469,940.15, representing a rise of about 163.5%[16] - The company's long-term borrowings stood at ¥985,500,000.00, up from ¥960,500,000.00, reflecting an increase of approximately 2.6%[16] - The retained earnings increased to ¥1,864,690,738.17 from ¥1,807,249,349.68, showing a growth of about 3.16%[17] Research and Development - R&D investment totaled ¥49,700,532.11, which is 28.16% higher than the previous year, accounting for 9.83% of operating revenue, an increase of 3.97 percentage points[5] Government Support - The company received government subsidies amounting to ¥14,369,756.68 during the reporting period[6] Other Financial Activities - Cash outflow from investing activities for Q1 2023 was ¥588.14 million, compared to ¥1,058.05 million in Q1 2022[23] - The net cash flow from financing activities was $153.81 million, compared to a negative $22.28 million in the previous period[24] - The total cash and cash equivalents at the end of the period amounted to $5.85 billion, down from $8.21 billion year-over-year[24] - The cash and cash equivalents decreased by $374.66 million during the quarter, compared to a decrease of $940.91 million in the same period last year[24] - The impact of exchange rate changes on cash and cash equivalents was a negative $19.58 million, compared to a negative $5.03 million in the previous year[24] - The total cash outflow from financing activities was $143.49 million, compared to $308.59 million in the previous period[24] Profit Decline Reasons - The decline in net profit was primarily due to decreased sales of the long-chain dicarboxylic acid series and increased one-time expenses and R&D costs[7]

Financial Performance - In 2022, the company achieved a net profit of ¥553,265,973.38, with the parent company contributing ¥59,271,829.16 to this figure[7]. - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-over-year increase of 20%[14]. - The company's operating revenue for 2022 was CNY 2,441,103,971.54, representing a year-on-year increase of 3.28%[25]. - The net profit attributable to shareholders for 2022 was CNY 553,265,973.38, a decrease of 6.97% compared to the previous year[25]. - The basic earnings per share for 2022 was CNY 0.95, down 6.86% from CNY 1.02 in 2021[26]. - The company reported a net profit of CNY 67,085,275.78 in Q4 2022, a significant decrease compared to previous quarters[28]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[14]. - The company’s cash dividend distribution plan has been approved by the board and requires shareholder meeting approval[7]. - The total cash dividend amount (including tax) is RMB 199,360,120.21, accounting for 36.03% of the net profit attributable to ordinary shareholders of the listed company[170]. Research and Development - Investment in R&D increased by 30% in 2022, focusing on synthetic biology technologies and new material development[14]. - The company emphasizes continuous innovation and aims to enhance existing product technologies while launching valuable new bio-manufacturing products[3]. - The company has developed breakthrough processes for bio-based high-temperature nylon, demonstrating significant cost-performance advantages[2]. - The company is focusing on the development of biological chemical engineering, integrating genetic engineering, cell engineering, and enzyme engineering to optimize production processes[16]. - The company’s R&D focuses on projects with competitive, forward-looking, social significance, and commercial value[43]. - The company has achieved industrialization of bio-based hexamethylenediamine, with an investment of ¥34.34 million, positioning itself at an international leading level[68]. - The company has obtained 70 invention patents and 6 utility model patents during the reporting period, totaling 259 invention patents and 59 utility model patents to date[63][64]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[14]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the biotechnology sector[16]. - A strategic acquisition of a biotechnology firm was completed, expected to enhance the company's product portfolio and increase market competitiveness[14]. - The company is exploring potential acquisitions to strengthen its portfolio, with a focus on companies in the H industry[146]. - The company is focusing on direct sales, with a small portion of sales through non-terminal trading partners, utilizing third-party logistics for domestic and international deliveries[41]. Sustainability and Environmental Impact - The company emphasizes the importance of biological processes in its production methods, aligning with sustainability goals[16]. - The company is committed to sustainable development, aligning with national policies aimed at achieving carbon neutrality by 2060[60]. - The company has invested 20,023.2 million yuan in environmental protection during the reporting period[185]. - Kaisa (Taiyuan) Biotechnology achieved zero wastewater discharge by fully recycling treated water at the Shanxi Synthetic Biological Industry Ecological Park[190]. - The company has developed emergency response plans for environmental incidents, which have been filed with the relevant authorities[196]. Governance and Management - The company has established a governance structure that includes a shareholders' meeting, board of directors, independent directors, supervisory board, and senior management, along with specialized committees such as the strategic committee and audit committee[139]. - The total pre-tax remuneration for senior management during the reporting period amounted to CNY 1,226.83 million, with individual remuneration for key personnel detailed[145]. - The company has expanded its management team with new appointments, including a Chief Operating Officer as of January 2023[148]. - The company has a history of successful leadership transitions, ensuring continuity in its strategic direction and operational execution[148]. - The company has implemented internal control measures focusing on financial activities, investment business, procurement, production management, and sales business[180]. Product Development and Innovation - The company is actively developing bio-based polyamide applications, with a focus on high-temperature polyamide and continuous fiber-reinforced bio-based polyamide composite materials[34]. - The company is developing technologies for the collection, pretreatment, and hydrolysis of agricultural waste, aiming to utilize straw and other biomass as raw materials for bio-manufacturing[130]. - The company is focusing on developing bio-based nylon products, which exhibit properties similar to traditional chemical nylon 66, thus facing direct competition but also offering unique advantages in specific applications[127]. - The company is enhancing collaboration with downstream customers to expand market applications for its products[35]. Financial Management and Risks - The company has significant accounts receivable, which has created operational cash flow pressure, although the main customers are large enterprises with good credit status[89]. - The company faces risks related to inventory devaluation due to difficulties in accurately predicting future customer demand, which may lead to excess inventory levels[90]. - The company benefits from tax incentives as a high-tech enterprise, but changes in tax laws or loss of high-tech status could negatively impact financial performance[92]. - The company is exposed to market competition risks, with potential new entrants in the bio-based long-chain dicarboxylic acid and bio-based hexamethylenediamine markets[95].

证券代码：688065 证券简称：凯赛生物 公告编号：2023-010 上海凯赛生物技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 4 月 24 日(星期一)至 4 月 28 日(星期五)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 cathaybiotech_info@cathaybiotech.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 5 月 4 日 下午 16:00-17:00 会议召开时间：2023 年 5 月 4 日(星期四) 下午 16:00-17:00 会议召开 ...